The European Commission has awarded marketing approval to Sixmo, a subdermal buprenorphine implant from Titan Therapeutics and Molteni, in all 28 European Member states for the substitution treatment of opioid dependence.
Specifically, the approval refers to adult patients who are clinically stable and require no more than 8mg per day of sublingual buprenorphine, “within a framework of medical, social and psychological treatment.
Image caption: Image Credit: US Air Force Valerie Monroy
